CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Discontinuation of Cholinesterase Inhibitors in Adults with Dementia: Clinical Effectiveness and Guidelines

Last updated: November 13, 2019
Project Number: RB1408-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary of Abstracts
Result type: Report

Question

  1. What is the clinical effectiveness of discontinuing cholinesterase inhibitors in adults who have dementia?
  2. What are the evidence-based guidelines for discontinuing cholinesterase inhibitors in adults who have dementia?

Key Message

One systematic review with meta-analysis and five randomized controlled trials were identified regarding the clinical effectiveness of discontinuing cholinesterase inhibitors in adults who have dementia. Three evidence-based guidelines were identified regarding discontinuing cholinesterase inhibitors in adults who have dementia.